Skip to main content
. 2020 Apr 29;21(9):3145. doi: 10.3390/ijms21093145

Figure 7.

Figure 7

Efficacies of BJ-3105, tofacitinib, and sulfasalazine on tumor formation in AOM/DSS-treated mice. WT and AMPKαfl/fl-Lyz2-Cre mice were used for the AOM/DSS-induced colitis-associated cancer model experiment. WT and AMPKαfl/fl-Lyz2-Cre mice were used for the AOM/DSS-induced colitis-associated cancer model experiment. BJ-3105 (1 and 3 mg/kg), tofacitinib (30 mg/kg), or sulfasalazine (SSZ) (300 mg/kg) were administered orally. (a) Changes in body weight. (b) The representative view of the distal colon lumen. In the macroscopic examination, tumors larger than 2 mm in diameter were counted, and the numbers of tumors are presented as means ± standard errors (n = 5). *p < 0.05, versus sham-operated WT mice. #p < 0.05, versus AOM/DSS-treated WT mice. $p < 0.05, versus sham-operated AMPKαfl/fl-Lyz2-Cre mice. &p < 0.05, versus AOM/DSS-treated mice. §p < 0.05, versus tofacitinib-treated WT or AMPKαfl/fl-Lyz2-Cre mice.